


Status: Currently Official on 17-Feb-2025  
Official Date: Official as of 01-May-2020  
Document Type: USP Monographs  
DocId: GUID-6B335FC2-CC1A-4CD7-AD5D-D6CAC65475D1\_6\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M83650\\_06\\_01](https://doi.org/10.31003/USPNF_M83650_06_01)  
DOI Ref: 7e388

© 2025 USPC  
Do not distribute

# Timolol Maleate



$C_{13}H_{24}N_4O_3S \cdot C_4H_4O_4$  432.49  
2-Propanol, 1-[(1,1-dimethylethyl)amino]-3- [[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy]-, (S)-, (Z)-2-butenedioate (1:1) (salt);  
(-)-1-(tert-Butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate (1:1) (salt) CAS RN®: 26921-17-5; UNII: P8Y54F701R.

**DEFINITION**  
Timolol Maleate contains NLT 98.0% and NMT 102.0% of timolol maleate ( $C_{13}H_{24}N_4O_3S \cdot C_4H_4O_4$ ), calculated on the dried basis.

**IDENTIFICATION**

Change to read:

- **A.** ▲ [SPECTROSCOPIC IDENTIFICATION TESTS \(197\)](#), *Infrared Spectroscopy*: 197M or 197A ▲ (CN 1-May-2020)
- **B.** The retention time of the timolol peak of the *Sample solution* corresponds to that of the *System suitability solution*, as obtained in the *Enantiomeric Purity* test.

**ASSAY**

• **PROCEDURE**

**Solution A:** Dilute 0.5 mL of [trifluoroacetic acid](#) with [water](#) to 1 L.  
**Solution B:** Dilute 0.5 mL of [trifluoroacetic acid](#) with [acetonitrile](#) to 1 L.  
**Mobile phase:** See [Table 1](#).

Table 1

Time (min)	Solution A (%)	Solution B (%)
0	84	16
2.4	84	16
8	20	80
8.1	84	16
11	84	16

**Diluent:** [Methanol](#) and [water](#) (60:40)  
**System suitability solution:** 100 µg/mL of [USP Timolol Maleate RS](#) and 10 µg/mL of [USP Timolol Related Compound D RS](#) in *Diluent*  
**Standard solution:** 100 µg/mL of [USP Timolol Maleate RS](#) in *Diluent*  
**Sample solution:** 100 µg/mL of Timolol Maleate in *Diluent*  
**Chromatographic system**  
(See [Chromatography \(621\)](#), *System Suitability*.)

**Mode:** LC**Detector:** UV 295 nm**Column:** 2.1-mm × 10-cm; 2.6-μm packing [L1](#)**Autosampler temperature:** 4°**Flow rate:** 0.4 mL/min**Injection volume:** 2.5 μL**System suitability****Samples:** *System suitability solution* and *Standard solution***Suitability requirements****Resolution:** NLT 2 between timolol and timolol related compound D, *System suitability solution***Tailing factor:** NMT 2.0, *Standard solution***Relative standard deviation:** NMT 0.73%, *Standard solution***Analysis****Samples:** *Standard solution* and *Sample solution*Calculate the percentage of timolol maleate ( $C_{13}H_{24}N_4O_3S \cdot C_4H_4O_4$ ) in the portion of Timolol Maleate taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

 $r_U$  = peak response of timolol from the *Sample solution* $r_S$  = peak response of timolol from the *Standard solution* $C_S$  = concentration of [USP Timolol Maleate RS](#) in the *Standard solution* (μg/mL) $C_U$  = concentration of Timolol Maleate in the *Sample solution* (μg/mL)**Acceptance criteria:** 98.0%–102.0% on the dried basis**IMPURITIES**

- [RESIDUE ON IGNITION \(281\)](#): NMT 0.1%

**Change to read:**

- **ORGANIC IMPURITIES**

**Solution A, Solution B, Mobile phase, Diluent, and Chromatographic system:** Proceed as directed in the Assay.**▲Sensitivity solution:** 0.5 μg/mL of [USP Timolol Maleate RS](#) in *Diluent*▲ (USP 1-Dec-2019)**System suitability solution:** 100 μg/mL each of [USP Timolol Maleate RS](#), [USP Timolol Related Compound B RS](#), [USP Timolol Related Compound C RS](#), [USP Timolol Related Compound D RS](#), [USP Timolol Related Compound E RS](#), and [USP Timolol Related Compound F RS](#) in *Diluent*. [NOTE—Prepare fresh and analyze immediately as [USP Timolol Related Compound E RS](#) degrades rapidly.]**Standard solution:** 1 μg/mL of [USP Timolol Maleate RS](#) and 4 μg/mL each of [USP Timolol Related Compound B RS](#), [USP Timolol Related Compound C RS](#), [USP Timolol Related Compound D RS](#), [USP Timolol Related Compound E RS](#), and [USP Timolol Related Compound F RS](#) in *Diluent*. Sonicate if needed for 0.5 min.**Sample solution:** 1 mg/mL of Timolol Maleate in *Diluent***System suitability****Samples:** ▲*Sensitivity solution*,▲ (USP 1-Dec-2019) *System suitability solution*, and *Standard solution***Suitability requirements****Resolution:** NLT 2.0 between timolol and timolol related compound D, *System suitability solution***Relative standard deviation:** NMT 4.0% for timolol, *Standard solution***▲Signal-to-noise ratio:** NLT 10 for timolol, *Sensitivity solution*▲ (USP 1-Dec-2019)**Analysis****Samples:** *Standard solution* and *Sample solution*

▲Calculate the percentage of timolol maleate ester (free base of timolol related compound E) in the portion of Timolol Maleate taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$$

 $r_U$  = peak response of timolol maleate ester from the *Sample solution* $r_S$  = peak response of timolol maleate ester from the *Standard solution*

$C_s$  = concentration of [USP Timolol Related Compound E RS](#) in the *Standard solution* (µg/mL)

$C_U$  = concentration of Timolol Maleate in the *Sample solution* (µg/mL)

$M_{r1}$  = molecular weight of timolol maleate ester, 414.48

$M_{r2}$  = molecular weight of timolol related compound E, 530.55

Calculate the percentage of timolol bistiadiazol analog (free base of timolol related compound C) in the portion of Timolol Maleate taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$$

$r_U$  = peak response of timolol bistiadiazol from the *Sample solution*

$r_S$  = peak response of timolol bistiadiazol from the *Standard solution*

$C_s$  = concentration of [USP Timolol Related Compound C RS](#) in the *Standard solution* (µg/mL)

$C_U$  = concentration of Timolol Maleate in the *Sample solution* (µg/mL)

$M_{r1}$  = molecular weight of timolol bistiadiazol, 485.62

$M_{r2}$  = molecular weight of timolol related compound C, 601.69▲ (USP 1-Dec-2019)

Calculate the percentage of ▲timolol related compound B, D, or F▲ (USP 1-Dec-2019) in the portion of Timolol Maleate taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response of ▲timolol related compound B, D, or F▲ (USP 1-Dec-2019) from the *Sample solution*

$r_S$  = peak response of ▲timolol related compound B, D, or F▲ (USP 1-Dec-2019) from the *Standard solution*

$C_s$  = concentration of ▲[USP Timolol Related Compound B RS](#), [USP Timolol Related Compound D RS](#), or [USP Timolol Related Compound F RS](#)▲ (USP 1-Dec-2019) in the *Standard solution* (µg/mL)

$C_U$  = concentration of Timolol Maleate in the *Sample solution* (µg/mL)

Calculate the percentage of any individual unspecified impurity in the portion of Timolol Maleate taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response of any individual unspecified impurity from the *Sample solution*

$r_S$  = peak response of timolol from the *Standard solution*

$C_s$  = concentration of [USP Timolol Maleate RS](#) in the *Standard solution* (µg/mL)

$C_U$  = concentration of Timolol Maleate in the *Sample solution* (µg/mL)

**Acceptance criteria:** See [Table 2](#). ▲The reporting threshold is 0.05%.▲ (USP 1-Dec-2019)

**Table 2**

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Timolol related compound B	0.5	0.4
Timolol related compound D	0.8	0.4

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Timolol maleate	1.0	—
▲Timolol maleate ester <sup>a</sup> ▲ (USP 1-Dec-2019)	1.4	0.4
▲Timolol bithiadiazol analog <sup>b</sup> ▲ (USP 1-Dec-2019)	1.8	0.4
Timolol related compound F	2.0	0.4
Any individual unspecified impurity	—	0.10
▲Total impurities▲ (USP 1-Dec-2019)	—	1.0

▲<sup>a</sup> (S)-3-(tert-Butylamino)-1-(4-morpholino-1,2,5-thiadiazol-3-yloxy)propan-2-yl hydrogen maleate.

<sup>b</sup> N-(tert-Butyl)-2,3-bis(4-morpholino-1,2,5-thiadiazol-3-yloxy)propan-1-amine.▲ (USP 1-Dec-2019)

#### Change to read:

##### • ENANTIOMERIC PURITY

Prepare all solutions in low-actinic glassware protected from light.

**Mobile phase:** [Diethylamine](#), [2-propanol](#), and [hexane](#) (2:40:960)

**Diluent:** [Methylene chloride](#) and [2-propanol](#) (25:75)

**System suitability solution:** 0.03 mg/mL each of [USP Timolol Maleate RS](#) and [USP Timolol Related Compound A RS](#) in *Diluent*

**Standard solution:** 0.03 mg/mL of [USP Timolol Related Compound A RS](#) in *Diluent*

**Sample solution:** 3 mg/mL of Timolol Maleate in *Diluent*

##### Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

**Mode:** LC

**Detector:** UV 297 nm

**Column:** 4.6-mm × 25-cm; 5-μm packing [L40](#)

**Flow rate:** 1 mL/min

**Injection volume:** 5 μL

##### System suitability

**Samples:** *System suitability solution* ▲ and *Standard solution* ▲ (USP 1-Dec-2019)

##### Suitability requirements

**Resolution:** NLT 4.0 between the timolol related compound A and timolol peaks, *System suitability solution*

**Relative standard deviation:** NMT 1.5% for ▲ the timolol related compound A peak, *Standard solution* ▲ (USP 1-Dec-2019)

**Signal-to-noise ratio:** NLT 10 for the timolol related compound A peak, ▲ *Standard solution* ▲ (USP 1-Dec-2019)

##### Analysis

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of timolol related compound A in the portion of Timolol Maleate taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response of timolol related compound A from the *Sample solution*

$r_S$  = peak response of timolol related compound A from the *Standard solution*

$C_S$  = concentration of [USP Timolol Related Compound A RS](#) in the *Standard solution* (mg/mL)

$C_U$  = concentration of Timolol Maleate in the *Sample solution* (mg/mL)

**Acceptance criteria:** NMT 1.0%

**SPECIFIC TESTS**• **pH** (791).**Sample solution:** 20 mg/mL of Timolol Maleate in [water](#)**Acceptance criteria:** 3.8–4.3• **Loss on Drying** (731).**Analysis:** Dry under vacuum at 100° to constant weight.**Acceptance criteria:** NMT 0.5%**ADDITIONAL REQUIREMENTS****Change to read:**

- **PACKAGING AND STORAGE:** Preserve in well-closed containers, ▲protected from light. ▲ (USP 1-Dec-2019)

• **USP REFERENCE STANDARDS** (11).[USP Timolol Maleate RS](#)[USP Timolol Related Compound A RS](#)(R)-1-(*tert*-Butylamino)-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy)propan-2-ol maleate. $C_{13}H_{24}N_4O_3S \cdot C_4H_4O_4$  432.49[USP Timolol Related Compound B RS](#)3-(*tert*-Butylamino)-2-(4-morpholino-1,2,5-thiadiazol-3-yloxy)propan-1-ol. $C_{13}H_{24}N_4O_3S$  316.42[USP Timolol Related Compound C RS](#)*N*-(*tert*-Butyl)-2,3-bis(4-morpholino-1,2,5-thiadiazol-3-yloxy)propan-1-amine maleate. $C_{19}H_{31}N_7O_4S_2 \cdot C_4H_4O_4$  601.69[USP Timolol Related Compound D RS](#)

4-Morpholino-1,2,5-thiadiazol-3-ol.

 $C_6H_9N_3O_2S$  187.22[USP Timolol Related Compound E RS](#)(S, Z)-4-({1-(*tert*-Butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]propan-2-yl}oxy)-4-oxobut-2-enoic acid maleate salt (1:1). $C_{17}H_{26}N_4O_6S \cdot C_4H_4O_4$  530.55[USP Timolol Related Compound F RS](#)

3-Chloro-4-morpholino-1,2,5-thiadiazol.

 $C_6H_8ClN_3OS$  205.67**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
TIMOLOL MALEATE	<a href="#">Documentary Standards Support</a>	SM22020 Small Molecules 2
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	SM22020 Small Molecules 2

**Chromatographic Database Information:** [Chromatographic Database](#)**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 44(5)

**Current DocID:** GUID-6B335FC2-CC1A-4CD7-AD5D-D6CAC65475D1\_6\_en-US**DOI:** [https://doi.org/10.31003/USPNF\\_M83650\\_06\\_01](https://doi.org/10.31003/USPNF_M83650_06_01)**DOI ref:** [7e388](#)